US · USD
TEVA
Teva Pharma Industries Ltd ADR
- Day's range
- US$38.52 – US$39.58
- Day's volume
- US$234m
- 52-week range
- US$18.95 – US$40.22
Follow TEVA on Fuolio
See how TEVA weighs in your net worth, what it has paid you and how far it is from your target allocation.
Create a free accountTEVA in numbers
- Market cap
- US$45.8bn
- P/E
- 64.88
- P/B
- 5.91
- Dividend yield (12m)
- 0.00%
- Net debt/EBITDA
- 0.33
TEVA trades at 64.88 times its earnings of the last 12 months.
TEVA price history
TEVA risk and return
Monthly closes adjusted for splits and distributions.
| Metric | 12 months | 36 months | 60 months |
|---|---|---|---|
| Return | +96.04% | +288.24% | +306.57% |
| Volatility (annualised) | 38.74% | 40.26% | 39.62% |
| Largest drawdown | -11.62% | -30.26% | -31.69% |
| Positive months | 9/12 | 23/36 | 34/60 |
How much did investing in TEVA return?
US$1,000.00 invested on 01/09/2021 would be worth US$4,065.71 today.
- Value today in TEVA
- US$4,065.71
- Return over the period
- +306.57%
- Return per year
- +32.39%
- In the S&P 500
- US$1,776.31
With dividends reinvested, before taxes and costs, at month-end closes. Past returns do not guarantee future ones.
TEVA fundamentals
Valuation
- P/E64.88
- P/B5.91
- EV/EBITDA18.00
- EV/EBIT29.10
- EV/Revenue3.31
- P/EBIT28.58
- P/S3.25
- P/OCF24.13
- P/FCF—
- Earnings yield3.44%
- PEG ratio—
- Earnings per shareUS$0.61
- Book value per shareUS$6.65
Debt
- Net debtUS$845m
- Net debt/EBITDA0.33
- Net debt/Equity0.11
- Debt/Equity0.58
- Current ratio0.88
- Quick ratio0.67
- Cash ratio0.23
Efficiency
- Gross margin64.41%
- EBITDA margin18.38%
- Operating margin11.37%
- Net margin5.01%
- Asset turnover0.35
Profitability
- ROE9.11%
- ROA1.77%
- ROIC18.33%
- Payout0.00%
Growth
- Revenue CAGR (5 years)-2.88%
- Earnings CAGR (5 years)—
- Revenue growth (year)—
- Earnings growth (year)—
- Revenue growth (quarter)—
- Earnings growth (quarter)—
What is TEVA's fair price?
Two classic value formulas, with today's numbers. The current price is US$39.31.
- Graham's fair price
- US$9.52
- 75.77% below the price
√(22.50 × US$0.61 × US$6.65)
Benjamin Graham paid no more than a P/E of 15 and a P/B of 1.5. Their product, 22.5, times earnings (EPS) and book value per share gives the fair price.
- Bazin's ceiling price
- —
- Does not apply to TEVA: it paid no distributions in the last five years.
Décio Bazin only bought shares yielding at least 6% a year in distributions. The ceiling price is the average dividend per share of recent years divided by 6%.
Graham ignores growth and debt; Bazin assumes past distributions will repeat. They are reference points for comparison, not a buy recommendation.
TEVA indicators by year
Multiples at each year's closing price; margins and returns from that year's accounts.
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E | 25.45 | -15.25 | -20.94 | -4.14 | 21.19 | -2.65 | -10.71 | -7.81 |
| P/B | 4.54 | 4.65 | 1.56 | 1.30 | 0.86 | 1.06 | 0.77 | 1.14 |
| EV/EBITDA | 10.80 | 31.02 | 6.39 | — | 2.65 | — | 8.26 | 81.54 |
| Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings per share | US$1.23 | -US$1.45 | -US$0.50 | -US$2.20 | US$0.38 | -US$3.64 | -US$0.91 | -US$1.97 |
| Book value per share | US$6.88 | US$4.74 | US$6.70 | US$7.02 | US$9.32 | US$9.14 | US$12.79 | US$13.50 |
| ROE | 17.83% | -30.50% | -7.45% | -31.34% | 4.06% | -39.80% | -7.15% | -14.62% |
| ROIC | 35.06% | -7.91% | 7.22% | -24.69% | 12.25% | -32.65% | -2.50% | -10.35% |
| Gross margin | 51.79% | 48.74% | 48.25% | 46.72% | 47.83% | 46.38% | 44.63% | 45.41% |
| EBITDA margin | 18.30% | 4.57% | 10.01% | -5.96% | 19.18% | -12.10% | 7.57% | 1.12% |
| Net margin | 8.17% | -9.91% | -3.53% | -16.39% | 2.63% | -23.95% | -5.92% | -11.77% |
| Net debt/EBITDA | -0.56 | -2.04 | -0.99 | — | -0.25 | — | -0.11 | -0.40 |
TEVA financial statements
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net revenue | US$17.3bn | US$16.5bn | US$15.8bn | US$14.9bn | US$15.9bn | US$16.7bn |
| Cost of sales | -US$8.3bn | -US$8.5bn | -US$8.2bn | -US$8bn | -US$8.3bn | -US$8.9bn |
| Gross profit | US$8.9bn | US$8.1bn | US$7.6bn | US$7bn | US$7.6bn | US$7.7bn |
| EBITDA | US$3.2bn | US$756m | US$1.6bn | -US$889m | US$3bn | -US$2bn |
| EBIT | US$2.2bn | -US$303m | US$433m | -US$2.2bn | US$1.7bn | -US$3.6bn |
| Net finance result | -US$934m | -US$981m | -US$1.1bn | -US$966m | -US$1.1bn | -US$834m |
| Profit before tax | US$1.2bn | -US$1.3bn | -US$624m | -US$3.2bn | US$658m | -US$4.4bn |
| Income tax | US$180m | -US$676m | US$7m | US$643m | -US$211m | US$168m |
| Net income | US$1.4bn | -US$1.6bn | -US$559m | -US$2.4bn | US$417m | -US$4bn |
Figures the company filed with the CVM. Debt excludes leases; each quarter is that quarter alone.
Does TEVA pay dividends?
Dividend yield per year
- 4.49%2017
- 0.00%2018
- 0.00%2019
- 0.00%2020
- 0.00%2021
- 0.00%2022
- 0.00%2023
- 0.00%2024
- 0.00%2025
- 0.00%2026
| Type | Last day to own | Payment | Per share |
|---|---|---|---|
| Dividend | 24/11/2017 | 12/12/2017 | US$0.09 |
| Dividend | 24/08/2017 | 14/09/2017 | US$0.09 |
| Dividend | 31/05/2017 | 22/06/2017 | US$0.34 |
| Dividend | 27/02/2017 | 20/03/2017 | US$0.34 |
| Dividend | 30/11/2016 | 20/12/2016 | US$0.34 |
About Teva Pharma Industries
- Sector
- Manufacturing
Questions about TEVA
How much is TEVA today?
TEVA is at US$39.31 (-0.73% on the day), last traded on 01/10/2026.
How much did TEVA pay in dividends in 2025?
TEVA paid US$0.00 per share in 2025, a dividend yield of 0.00%.
What are the P/E and P/B of TEVA?
TEVA trades at a P/E of 64.88 and a P/B of 5.91.
How much did TEVA return in 12 months?
TEVA returned 96.04% in 12 months, with annualised volatility of 38.74% and a largest drawdown of -11.62%.